Search
Rigel Pharmaceuticals Inc
RIGLAdd to Watchlist
38.720USD
+0.430+1.12%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
715.61MMarket Cap
1.91P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+1.12%
5 Days
+4.68%
1 Month
+28.98%
6 Months
-7.43%
Year to Date
-9.60%
1 Year
+107.61%
Key Figures
39.180Open
40.334High
573.91KVolume
1.91P/E TTM
9.27P/E Dynamic
--Dividend TTM
3.11%Turnover Ratio
38.290Prev. Close
38.145Low
17.82MTurnover
40.93P/E Static
1.79P/B
0.00%Div Yield TTM
107.04%ROA
52.24052wk High
2.59Volume Ratio
17.48MNet Profit
18.48MShares
20.2322EPS TTM
1.19Beta
174.08%ROE
18.14052wk Low
5.72%Amplitude
92.17%Gross Margin
715.61MMarket Cap
7.73Reward/Risk
3.41%Risk Rate
TradingKey Stock Score of Rigel Pharmaceuticals Inc
Currency: USD Updated: 2026-07-02Key Insights
Rigel Pharmaceuticals Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.20.In the medium term, the stock price is expected to trend up.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Rigel Pharmaceuticals Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Rigel Pharmaceuticals Inc Highlights
StrengthsRisks
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 151.78% year-on-year.
Fairly Valued
The company’s latest PE is 1.91, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 17.75M shares, increasing 4.23% quarter-over-quarter.
Held by ETHSX
Star Investor ETHSX holds 37.99K shares of this stock.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
54.200
Target Price
+38.83%
Upside Space
Rigel Pharmaceuticals Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Rigel Pharmaceuticals Inc Info
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in developing and providing novel therapies that significantly improve the lives of patients with hematologic disorders and cancer. It is focused on products that address signaling pathways that are critical to disease mechanisms. Its first product is TAVALISSE (fostamatinib disodium hexahydrate) tablets, the approved oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. Its second product is REZLIDHIA (olutasidenib) capsules for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test. Its GAVRETO (pralsetinib) product is a once daily, small molecule, oral, kinase inhibitor of wild type rearranged during transfection (RET) and oncogenic RET fusions.
Ticker SymbolRIGL
CompanyRigel Pharmaceuticals Inc
CEORodriguez (Raul R)
Website
Related Instruments
+1.62%
+3.50%
+6.14%
+3.96%
+3.31%
+3.72%
+3.55%
+3.40%
+4.21%
+1.80%
+6.03%
+2.95%
+4.62%
+3.68%
+2.35%
0.00%
+4.73%
+3.32%
+0.41%
+4.98%Popular Instruments
52968.200
+125.700 (+0.24%)
29578.100
+266.700 (+0.91%)
7502.300
+30.800 (+0.41%)
15011.000
+208.000 (+1.41%)
69414.000
+1266.000 (+1.86%)
6375.900
+23.100 (+0.36%)
68.973
+0.629 (+0.92%)
308.630
+14.250 (+4.84%)
194.830
-2.750 (-1.39%)
4175.590
+53.680 (+1.30%)
FAQs
What is the current price of Rigel Pharmaceuticals Inc (RIGL)?
The current price of Rigel Pharmaceuticals Inc (RIGL) is 38.72.
What is the symbol of Rigel Pharmaceuticals Inc?
The ticker symbol of Rigel Pharmaceuticals Inc is RIGL.
What is the 52-week high of Rigel Pharmaceuticals Inc?
The 52-week high of Rigel Pharmaceuticals Inc is 52.24.
What is the 52-week low of Rigel Pharmaceuticals Inc?
The 52-week low of Rigel Pharmaceuticals Inc is 18.14.
What is the market capitalization of Rigel Pharmaceuticals Inc?
The market capitalization of Rigel Pharmaceuticals Inc is 715.61M.
Is Rigel Pharmaceuticals Inc (RIGL) currently rated as Buy, Hold, or Sell?
According to analysts, Rigel Pharmaceuticals Inc (RIGL) has an overall rating of Buy, with a price target of 54.20.
What is the Earnings Per Share (EPS TTM) of Rigel Pharmaceuticals Inc (RIGL)?
The Earnings Per Share (EPS TTM) of Rigel Pharmaceuticals Inc (RIGL) is 20.40.